secwatch.observer — SEC 8-K summary
======================================

Issuer:     AI Financial Corp (AIFC)
CIK:        0000862861
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001628280-24-049241
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALT5 Sigma subsidiary signs non-binding term sheet to acquire Soin Bioscience for equity, milestones up to $60M
--------------------------------------------------------------------------------

- Non-binding term sheet signed Nov 19, 2024: Alyea Therapeutics to acquire 100% of Soin Bioscience from Dr. Amol Soin.
- Consideration: 10% Alyea common equity (forfeitable pre-IPO), $5M cash on first FDA approval, 5% royalty up to $40M, 10% of PRV sale proceeds up to $15M.
- Clawback: If Alyea no IPO by Dec 31, 2025, Dr. Soin can reclaim Soin Bio and Soin Thera for no consideration.
- Soin Bio's clear patch technology is investigational, pending clinical trials and FDA approval; delivers pain medication up to 8 hours.
- Binding exclusivity: Soin Bio cannot solicit other offers until Feb 28, 2025; subject to due diligence and definitive agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/862861/000162828024049241/0001628280-24-049241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/862861/000162828024049241/jan-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer